FDA
-
-
-
-
-
-
-
GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026
-
-
-
-
-
-
-
GeneDx launches prenatal whole genome sequencing test
-
-
-
-
-
-
-
GeneDx receives FDA breakthrough device designation for genome tests
-
-
322,963 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

